NEW YORK (GenomeWeb) – Global Genomics Group (G3) said today that it has entered into a research collaboration with Sanofi focused on identifying new signaling pathways and targets involved in the etiology of coronary artery disease.
Under the terms of the agreement, the partners will use G3's proprietary platform and data from its G  LOBAL database to explore the signaling pathways associated with low-density lipoprotein-cholesterol regulation. The goal is to better understand which patients could benefit from treatments that interfere with the activities of these pathways.
The information contained in the G3 repository is drawn from the Genetic Loci and Burden of Atherosclerotic Lesions (GLOBAL) clinical study, a prospective study aimed at characterizing novel disease networks and biomarkers in up to 10,000 patients. The database offers access to whole-genome sequencing, whole-genome methylation, whole-transcriptome sequencing, proteomics, metabolomics, lipidomics, lipoprotein proteomics, and coronary computed tomographic angiography collected from participating patients. As part of the project, the company partnered with Quintiles to perform RNA sequencing, miRNA sequencing, and methylation analysis for the study. It also signed agreements with Caprion and Metabolon to identify blood-based protein markers and to analyze biochemical data, respectively, for the study.
"Our G  LOBAL database has been developed as a tool that enables drug developers and biomedical research scientists to better understand molecular networks that underlie human disease and thus improve the drug discovery and development process," Szilard Voros, G3's founder and CEO, said in a statement. "We believe that precision phenotyping, pan-omics, and systems-biology driven bioinformatics are the key components of target identification, validation, and the elucidation of novel pathways."
G3 will receive undisclosed payments from Sanofi for the collaboration, the company said.